177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J. Morris, Daniel Castellano, Ken Herrmann, Johann S. de Bono, Neal D. Shore, Kim N., Michael J. Crosby, Josep M. Piulats, Aude Fléchon, Xiao X. Wei, Hakim Mahammedi, Guilhem Roubaud, Hana Študentová, James Nagarajah, Begoña Mellado, Álvaro Montesa-Pino, Euloge Kpamegan, Samson Ghebremariam, Teri Kreisl, Celine Wilke, Katja Lehnhoff, Oliver Sartor, Karim Fizazi
Topics & Concepts
MedicineTaxaneProstate cancerOncologyAndrogen receptorInternal medicineAndrogen deprivation therapyClinical trialCancerBreast cancerProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Diagnosis and Treatment